Steven George Hughes Avidity Biosciences, Inc. (RNA) insider trading activity

Steven George Hughes is Chief Medical Officer of Avidity Biosciences, Inc.. Currently has a direct ownership of 36,494 shares of RNA, which is worth approximately $2.58 Million. The most recent transaction as insider was on Jan 07, 2026, when has been sold 2,373 shares (Common Stock) at a price of $72.23 per share, resulting in proceeds of $171,401. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 36.5K

6.11% 3M change

57.75% 12M change

Total Value Held $2.58 Million

Steven George Hughes Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 07 2026	SELL Open market or private sale	$171,401 $72.23 p/Share	2,373 Reduced 6.11%	36,494 Common Stock
Oct 22 2025	SELL Open market or private sale	$105,015 $47.54 p/Share	2,209 Reduced 5.38%	38,867 Common Stock
Oct 22 2025	BUY Exercise of conversion of derivative security	$22,443 $10.16 p/Share	2,209 Added 5.1%	41,076 Common Stock
Sep 22 2025	SELL Open market or private sale	$89,600 $40.58 p/Share	2,208 Reduced 5.38%	38,867 Common Stock
Sep 22 2025	BUY Exercise of conversion of derivative security	$22,433 $10.16 p/Share	2,208 Added 5.1%	41,075 Common Stock
Sep 15 2025	SELL Open market or private sale	$70,022 $45.41 p/Share	1,542 Reduced 3.82%	38,867 Common Stock
Sep 15 2025	BUY Exercise of conversion of derivative security	$10,130 $6.57 p/Share	1,542 Added 3.68%	40,409 Common Stock

Aug 22 2025	SELL Open market or private sale	$102,451 $46.4 p/Share	2,208 Reduced 5.38%	38,867 Common Stock
Aug 22 2025	BUY Exercise of conversion of derivative security	$22,433 $10.16 p/Share	2,208 Added 5.1%	41,075 Common Stock
Aug 13 2025	SELL Open market or private sale	$71,949 $46.66 p/Share	1,542 Reduced 3.82%	38,867 Common Stock
Aug 13 2025	BUY Exercise of conversion of derivative security	$10,130 $6.57 p/Share	1,542 Added 3.68%	40,409 Common Stock
Aug 06 2025	SELL Open market or private sale	$3,480,489 $42.74 p/Share	81,434 Reduced 67.69%	38,867 Common Stock
Aug 06 2025	BUY Exercise of conversion of derivative security	$654,349 $13.79 p/Share	47,451 Added 34.39%	90,517 Common Stock
Mar 20 2025	SELL Open market or private sale	$297,492 $31.06 p/Share	9,578 Reduced 11.62%	72,850 Common Stock
Jan 21 2025	SELL Open market or private sale	$112,884 $28.6 p/Share	3,947 Reduced 4.57%	82,428 Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	25,000 Added 22.45%	86,375 Common Stock

Also insider at

ARCT

Arcturus Therapeutics Holdings Inc. Healthcare

Chief Development Officer

SGH